|

NX-2127 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Nurix Therapeutics, Inc.1

Indications

  • Waldenstrom Macroglobulinemia (WM)1
  • Small Lymphocytic Lymphoma (SLL)1
  • Marginal Zone Lymphoma (MZL)1
  • Primary Central Nervous System Lymphoma (PCNSL)1
  • Follicular Lymphoma ( FL)1

Duarte, California1 trial

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.